Imaging technique for diagnosing and evaluating brain gliomas
Clinical Study on CXCR4 PET/MRI Targeted Integrated Imaging for Grading Diagnosis, Molecular Typing, and Prognostic Evaluation of Brain Glioma
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · NCT06234319
This study tests a new imaging technique using a special contrast agent to see if it can help doctors better understand and classify brain tumors in patients before surgery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University (other) |
| Locations | 1 site (Chongqing, Chongqing) |
| Trial ID | NCT06234319 on ClinicalTrials.gov |
What this trial studies
This project evaluates the effectiveness of CXCR4 targeted PET/MRI imaging in grading and molecular typing of brain gliomas. Primary glioma patients will undergo imaging with a CXCR4 contrast agent prior to surgical resection, with post-operative histopathological analysis serving as the reference standard. The study aims to establish a prognostic evaluation model based on the imaging results. Experienced neuroradiologists will analyze the images to delineate tumor characteristics and assess various MRI and PET parameters.
Who should consider this trial
Good fit: Ideal candidates are adults diagnosed with primary glioma who are scheduled for surgical resection.
Not a fit: Patients who are pregnant, breastfeeding, or have conditions that affect imaging quality may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could enhance the accuracy of glioma diagnosis and prognosis, leading to better patient management.
How similar studies have performed: While the use of PET/MRI imaging is established, the specific application of CXCR4 targeting in glioma grading and prognosis is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients diagnosed with primary glioma based on clinical, imaging, and histopathological criteria; 2. The patient is at least 18 years old; 3. Participate in CXCR4 PET/MRI imaging within 15 days before surgery; 4. Surgical resection of glioma lesion tissue can be used for pathological analysis; 5. The patient voluntarily participates and signs the informed consent form. Exclusion Criteria: 1. Pregnant or breastfeeding patients; 2. The image quality of the imaging is poor and cannot be used for diagnosis and evaluation; 3. Molecular typing was not determined by histologic examination; 4. patients with claustrophobia; 5. Patients who are allergic to radioactive tracers and MRI contrast agents, and patients with renal insufficiency.
Where this trial is running
Chongqing, Chongqing
- Department of Nuclear Medicine, Daping Hospital of Army Medical University — Chongqing, Chongqing, China (RECRUITING)
Study contacts
- Principal investigator: Chen Xiao, Ph.D — Daping Hospital, Army Medical University
- Study coordinator: Du ZHenwei, Ph.D
- Email: peter11dzw@126.com
- Phone: +8618580503880
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Glioma